Suppr超能文献

血管内腹主动脉瘤修复术的临床疗效

Clinical efficacy of endovascular abdominal aortic aneurysm repair.

作者信息

Son Bong-Su, Chung Sung Woon, Lee Chungwon, Ahn Hyo Yeong, Kim Sangpil, Kim Chang Won

机构信息

Department of Thoracic and Cardiovascular Surgery, School of Medicine, Pusan National University, Korea.

出版信息

Korean J Thorac Cardiovasc Surg. 2011 Apr;44(2):142-7. doi: 10.5090/kjtcs.2011.44.2.142. Epub 2011 Apr 14.

Abstract

BACKGROUND

Endovascular aortic aneurysm repair (EVAR) has come into use and been widely extended because of the low complication rate and less-invasiveness. This article aimed to describe our experience in the treatment of abdominal aortic aneurysm with EVAR.

MATERIALS AND METHODS

A retrospective review was conducted for the 22 patients who underwent EVAR in a single hospital December 2001 to June 2009.

RESULTS

The mean age of the patients was 68.5±7.6 years. There were several risk factors and comorbidities in 20 patients (90.9%). The mean diameter of the aortic aneurysms was 61.2±12.9 mm. The mean length, diameter, and angle of the aneurysmal neck were 30.5±15.5 mm, 24.0±4.5 mm, and 43.9±16.0°, respectively. The mean follow-up period of the patients was 28.8±29.5 months. The 30-day postoperative mortality was none. Seven patients (31.8%) had endoleaks during the hospital stay and three patients (13.6%) had endoleaks during the follow-up period. One patient (4.5%) died due to a ruptured aortic aneurysm. The cumulative patient survival rates were 88.2%, 88.2%, and 70.6% at 1, 3, and 5 years of follow-up, respectively.

CONCLUSION

EVAR is currently a safe, feasible procedure for high risk patients with abdominal aortic aneurysm because of low postoperative complication and mortality if patients are selected properly and followed up carefully.

摘要

背景

血管内主动脉瘤修复术(EVAR)因其低并发症率和微创性已开始应用并广泛推广。本文旨在描述我们应用EVAR治疗腹主动脉瘤的经验。

材料与方法

对2001年12月至2009年6月在一家医院接受EVAR治疗的22例患者进行回顾性研究。

结果

患者的平均年龄为68.5±7.6岁。20例患者(90.9%)存在多种危险因素和合并症。主动脉瘤的平均直径为61.2±12.9mm。瘤颈的平均长度、直径和角度分别为30.5±15.5mm、24.0±4.5mm和43.9±16.0°。患者的平均随访期为28.8±29.5个月。术后30天死亡率为零。7例患者(31.8%)在住院期间发生内漏,3例患者(13.6%)在随访期间发生内漏。1例患者(4.5%)死于主动脉瘤破裂。随访1年、3年和5年时患者的累积生存率分别为88.2%、88.2%和70.6%。

结论

如果患者选择得当并进行仔细随访,由于术后并发症和死亡率低,EVAR目前是治疗高危腹主动脉瘤患者的一种安全、可行的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e185/3249290/597defb5651f/kjtcs-44-142-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验